Connect with us

TechCrunch

FindAir is a smart inhaler

FindAir is digitizing asthma therapy with smart inhaler technology. The TC Top Picks program showcases outstanding early-stage startups across these categories: AI/Machine Learning, Biotech/Healthtech, Blockchain, Fintech, Mobility, Privacy/Security, Retail/E-commerce, Robotics/IoT/Hardware, SaaS and Social Impact & Education. TechCrunch is a leading technology media property, dedicated to obsessively profiling startups, reviewing new Internet products, and breaking tech…

Published

on

FindAir is digitizing asthma therapy with smart inhaler technology.

The TC Top Picks program showcases outstanding early-stage startups across these categories: AI/Machine Learning, Biotech/Healthtech, Blockchain, Fintech, Mobility, Privacy/Security, Retail/E-commerce, Robotics/IoT/Hardware, SaaS and Social Impact & Education.

TechCrunch is a leading technology media property, dedicated to obsessively profiling startups, reviewing new Internet products, and breaking tech news.

Continue Reading
Advertisement
9 Comments

9 Comments

  1. Abhishek Rao Chimbili

    October 27, 2019 at 4:51 pm

    That is the most useless thing I’ve ever seen.

  2. Brandon S.

    October 27, 2019 at 4:52 pm

    You are supposed to use a spacer. The inhaler alone is not good. Not to mention there are some inhalers that already track the number of uses. This is pointless.

  3. Greg Nulik

    October 27, 2019 at 7:21 pm

    Hope the sensor supports a full dosage.

  4. polyannamoonbeam

    October 27, 2019 at 10:39 pm

    Not enough info …sensor tells you what your trigger was…? How? Blood prick analysis? Heartrate? Allergen analysis? Doctors are now instructed to ration patients to one Ventolin a month, two if you argue at length. There is no science to back up patients self diagnosed need for more, doctors differ on what is sufficient, how to measure severity and are often punitive/ biased against smokers. Many patients become resistant to their Ventolyn due to misuse, long term use.. tracking usage doesnt tell you whether patient needed to use more or less puffs for each event or just misused due to poor technique….severe attacks are not managed by Ventolin. Steroids,adrenalin, intravenous meds, full mask vaporised meds- we use all in winter for son.

  5. Pinitrius

    October 27, 2019 at 11:34 pm

    Being an allergist I was interested to see what this was about… But no! It gives some information about patient adherence to the treatment but as with many products/service it is trying to force a subscription down patients throat without providing real long term value! And the product itself is rendered useless after 12 months due to the non-removable battery!

    To me it is just a gimmick the way they chose to make it and charge for it! Sorry…

  6. TechPimp

    October 28, 2019 at 1:51 am

    I didn’t understand what the heck it does?

  7. Gezaei Teklay

    October 28, 2019 at 2:09 am

    I hope it is helpful for asthma

  8. Arthur

    October 28, 2019 at 9:12 am

    So it counts how many times you use an inhaler a day and displays it on an app?

  9. takeonparis

    October 29, 2019 at 12:15 am

    This is the dumbest interview I’ve ever seen. He doesn’t even bother to ask: “So what does your product DO?” Like what in the actual hell…

Leave a Reply

Your email address will not be published. Required fields are marked *

Science & Technology

The new competition for your cap table | Equity Podcast

The VC middleman is getting cut out faster than anyone expected. Family offices and private wealth firms are going direct: writing checks, taking board seats, even incubating companies from scratch. And more founders are starting to notice. In February alone, family offices made 41 direct investments, including one Midwest-based firm that led a $230 million…

Published

on

The VC middleman is getting cut out faster than anyone expected. Family offices and private wealth firms are going direct: writing checks, taking board seats, even incubating companies from scratch. And more founders are starting to notice. In February alone, family offices made 41 direct investments, including one Midwest-based firm that led a $230 million Series B into an AI chip startup.

On this episode of TechCrunch’s Equity podcast, Rebecca Bellan caught up with Mitch Stein and Ari Schottenstein, founder and head of alternatives at ARENA Private Wealth, to find out what this shift means for founders, cap tables, and the future of AI investment.

Subscribe to Equity on YouTube, Apple Podcasts, Overcast, Spotify and all the casts. You also can follow Equity on X and Threads, at @EquityPod.

Chapters:

00:00 Intro

03:13 Why family offices are going direct now

06:03 The gen 2 & gen 3 family office shift

07:22 Is this strategic or just AI FOMO?

10:17 How Arena got into the Positron deal

14:30 Why founders want private wealth on their cap table

18:31 Due diligence on technical companies

21:56 Red flags founders should watch for

25:04 Are VCs threatened by this trend?

27:47 Taking board seats & level of involvement

34:17 Outro

Continue Reading

Science & Technology

OpenAI shuts down Sora while Meta gets shut out in court | Equity Podcast

When an 82-year-old Kentucky woman was offered $26 million from an AI company that wanted to build a data center on her land, she said no. Sure, that same company can try to rezone 2,000 acres nearby anyway, but as AI infrastructure stretches further into the real world, the real world is starting to push…

Published

on

When an 82-year-old Kentucky woman was offered $26 million from an AI company that wanted to build a data center on her land, she said no. Sure, that same company can try to rezone 2,000 acres nearby anyway, but as AI infrastructure stretches further into the real world, the real world is starting to push back.

That tension is everywhere this week, from OpenAI shutting down its Sora app to courts finally starting to hold social platforms accountable. On this episode of TechCrunch’s Equity podcast, Kirsten Korosec, Anthony Ha, and Sean O’Kane dig into what it looks like when the AI hype cycle meets reality.

Subscribe to Equity on YouTube, Apple Podcasts, Overcast, Spotify and all the casts. You also can follow Equity on X and Threads, at @EquityPod.

Chapters:

00:00 Intro

00:30 Would you turn down $26M for your farm?

03:56 Rivals Kalshi & Polymarket CEOs are investing together

10:28 Deals for drones: Zipline, Brinc & Lucid Bots

18:17 Kleiner Perkins goes all-in on AI with $3.5B raise

22:52 OpenAI shuts down Sora

28:04 Meta gets hit with dual verdicts

34:56 Outro

Continue Reading

Science & Technology

How soap opera-TikTok hybrids became a billion-dollar market | Equity Podcast

Over the past few years, a new category of mobile apps has quietly exploded into a multi-billion dollar business. They’re called “micro dramas” — short-form, mobile-first scripted shows designed to be watched vertically on your phone. Think soap opera meets TikTok, complete with secret billionaire romances, disapproving werewolf mothers-in-law, and cliffhangers engineered to keep users…

Published

on

Over the past few years, a new category of mobile apps has quietly exploded into a multi-billion dollar business. They’re called “micro dramas” — short-form, mobile-first scripted shows designed to be watched vertically on your phone. Think soap opera meets TikTok, complete with secret billionaire romances, disapproving werewolf mothers-in-law, and cliffhangers engineered to keep users tapping. The leading app, ReelShort, made $1.2 billion in consumer spending last year alone.

On this episode of TechCrunch’s Equity podcast, Rebecca Bellan and TechCrunch senior reporter Amanda Silberling sit down with Henry Soong, founder of Watch Club, who thinks the micro drama industry is still “in its MySpace era.” He has a vision for what the Facebook moment could look like.

Subscribe to Equity on YouTube, Apple Podcasts, Overcast, Spotify and all the casts. You also can follow Equity on X and Threads, at @EquityPod.

Chapters:

00:00 Intro

01:11 Why micro dramas, and why now?

04:25 What makes Watch Club different

07:29 The monetization model problem

18:52 Optimizing for intentionality, not engagement

24:23 Why Quibby failed (content, product & business model)

28:22 Defensibility: tech company or studio?

31:36 AI, the WGA, and the future of storytelling

33:44 Outro

Continue Reading

Trending